Sec Form 4 Filing - Kung Frank @ AMYRIS, INC. - 2018-08-17

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Kung Frank
2. Issuer Name and Ticker or Trading Symbol
AMYRIS, INC. [ AMRS]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O AMYRIS, INC., 5885 HOLLIS STREET, SUITE 100
3. Date of Earliest Transaction (MM/DD/YY)
08/17/2018
(Street)
EMERYVILLE, CA94608
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/17/2018 M 964,927 ( 1 ) A $ 4.26 3,448,664 I by Vivo Capital Fund VIII, L.P. ( 2 )
Common Stock 08/17/2018 M 133,246 ( 1 ) A $ 4.26 476,220 I by Vivo Capital Surplus Fund VIII, L.P. ( 2 )
Common Stock 08/17/2018 S( 3 ) 2,439,848 D $ 6.2188 1,008,816 I By Vivo Capital Fund VIII, L.P. ( 2 )
Common Stock 08/17/2018 S( 3 ) 336,914 D $ 6.2188 139,306 I By Vivo Capital Surplus Fund VIII, L.P. ( 2 )
Common Stock 08/17/2018 M 3,465,693 A $ 4.4 ( 4 ) 4,474,509 I By Vivo Capital Fund VIII, L.P. ( 2 )
Common Stock 08/17/2018 M 478,571 A $ 4.4 ( 4 ) 617,877 I By Vivo Capital Surplus Fund VIII, L.P. ( 2 )
Common Stock 08/20/2018 S( 3 ) 1,008,816 D $ 6.2188 3,465,693 I By Vivo Capital Fund VIII, L.P. ( 2 )
Common Stock 08/20/2018 S( 3 ) 139,306 D $ 6.2188 478,571 I By Vivo Capital Surplus Fund VIII, L.P. ( 2 )
Common Stock 08/20/2018 M 1,432,977 A $ 4.4 ( 4 ) 4,898,670 I By Vivo Capital Fund VIII, L.P. ( 2 )
Common Stock 08/20/2018 M 197,877 A $ 4.4 ( 4 ) 676,448 I By Vivo Capital Surplus Fund VIII, L.P. ( 2 )
Common Stock 4,266 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series D Convertible Preferred Stock $ 4.26 08/17/2018 M 4,110.589 08/03/2017 ( 5 ) Common Stock 964,927 ( 1 ) $ 0 7,275.3593 I By Vivo Capital Fund VIII, L.P. ( 2 )
Series D Convertible Preferred Stock $ 4.26 08/17/2018 M 567.628 08/03/2017 ( 5 ) Common Stock 133,246 ( 1 ) $ 0 1,004.6357 I By Vivo Capital Surplus Fund VIII, L.P. ( 2 )
Warrant (Right to Buy) $ 4.4 08/17/2018 M 3,465,693 ( 4 ) 08/03/2017 08/03/2022 Common Stock 3,465,693 $ 0 1,432,977 I By Vivo Capital Fund VIII, L.P. ( 2 )
Warrant (Right to Buy) $ 4.4 08/17/2018 M 478,571 ( 4 ) 08/03/2017 08/03/2022 Common Stock 478,571 $ 0 197,877 I By Vivo Capital Surplus Fund VIII, L.P. ( 2 )
Warrant (Right to Buy) $ 0.0001 08/17/2018 D 0 ( 6 ) 05/23/2018 05/23/2023 Common Stock ( 6 ) ( 6 ) 0 ( 6 ) I By Vivo Capital Fund VIII, L.P. ( 2 )
Warrant (Right to Buy) $ 0.0001 08/17/2018 D 0 ( 6 ) 05/23/2018 05/23/2023 Common Stock ( 6 ) ( 6 ) 0 ( 6 ) I By Vivo Capital Surplus Fund VIII, L.P. ( 2 )
Warrant (Right to Buy) $ 7.52 08/17/2018 A 4,488,072 02/17/2019 11/17/2019 Common Stock 4,488,072 ( 7 ) 4,488,072 I By Vivo Capital Fund VIII, L.P. ( 2 )
Warrant (Right to Buy) $ 7.52 08/17/2018 A 619,749 02/17/2019 11/17/2019 Common Stock 619,749 ( 7 ) 619,749 I By Vivo Capital Surplus Fund VIII, L.P. ( 2 )
Warrant (Right to Buy) $ 4.4 08/20/2018 M 1,432,977 ( 4 ) 08/03/2017 08/03/2022 Common Stock 1,432,977 $ 0 0 I By Vivo Capital Fund VIII, L.P. ( 2 )
Warrant (Right to Buy) $ 4.4 08/20/2018 M 197,877 ( 4 ) 08/03/2017 08/03/2022 Common Stock 197,877 $ 0 0 I By Vivo Capital Surplus Fund VIII, L.P. ( 2 )
Warrant (Right to Buy) $ 7.52 08/20/2018 A 1,855,706 02/20/2019 11/20/2019 Common Stock 1,855,706 ( 7 ) 1,855,706 I By Vivo Capital Fund VIII, L.P. ( 2 )
Warrant (Right to Buy) $ 7.52 08/20/2018 A 256,251 02/20/2019 11/20/2019 Common Stock 256,251 ( 7 ) 256,251 I By Vivo Capital Surplus Fund VIII, L.P. ( 2 )
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Kung Frank
C/O AMYRIS, INC.
5885 HOLLIS STREET, SUITE 100
EMERYVILLE, CA94608
X
Signatures
/s/ Frank Kung by Stephen Dobson, Attorney-in-Fact 08/21/2018
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Reflects the conversion of shares of the Issuer's Series D Convertible Preferred Stock issued on August 3, 2017. Each share of Series D Convertible Preferred Stock has a stated value of $1,000 and is convertible at any time at the option of the holder into common stock of the Issuer, subject to a 9.99% beneficial ownership limit.
( 2 )The General Partner of the holder is Vivo Capital VIII, LLC, of which the Reporting Person is a voting member. The Reporting Person may be deemed to share voting and dispositive power over these shares with four (4) other voting members. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes.
( 3 )Reflects the sale of common stock pursuant to that certain Underwriting Agreement, dated August 17, 2018, among the Issuer, Vivo Capital Fund VIII, L.P., Vivo Capital Surplus Fund VIII, L.P., the other selling stockholders party thereto and B. Riley FBR, Inc. as underwriter.
( 4 )Reflects the exercise of common stock purchase warrants (the "Cash Warrants") issued on August 3, 2017. In connection with such exercise, (i) the exercise price of the Cash Warrants was reduced from $6.39 per share to $4.40 per share and (ii) the 9.99% beneficial ownership limit applicable to the Cash Warrants was removed.
( 5 )The Series D Convertible Preferred Stock has no expiration date.
( 6 )Reflects the surrender of common stock purchase warrants issued on August 3, 2017 to provide the holders with full-ratchet anti-dilution protection with respect to the conversion price of their Series D Convertible Preferred Stock (the "Dilution Warrants"), to the Issuer for cancellation pursuant to the Warrant Exercise Agreements (as defined below). At the time of surrender, the Dilution Warrants were not exercisable for any shares.
( 7 )The warrants were issued pursuant to those certain Warrant Exercise Agreements, each dated August 17, 2018, between the Issuer and each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. (the "Warrant Exercise Agreements") in exchange for such holders exercising their Cash Warrants for cash and surrendering their Dilution Warrants for cancellation.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.